Home / Pharma Healthcare / GLOBAL CABAZITAXEL MARKET 2019 BY MANUFACTURERS, REGIONS, TYPE AND APPLICATION, FORECAST TO 2024

GLOBAL CABAZITAXEL MARKET 2019 BY MANUFACTURERS, REGIONS, TYPE AND APPLICATION, FORECAST TO 2024

  • Id : RNR-264800
  • Category : Pharma Healthcare
  • Publish Date : Apr-19
  • Publisher : Research-N-Reports
  • Pages : 123
  • Format : PDF
License Type

Description
Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.

Scope of the Report:
Global cabazitaxel production regions are mainly distributed in USA and Europe. There is no doubt that USA is the largest production region in the world. In the future, we predict that there will be more and more cabazitaxel suppliers as soon as Sanofi?s Cabazitaxel patent expired. By 2024, global production will be 1427.4 Kg. 
Currently, there are four major cabazitaxel API suppliers globally, including Sanofi, Tapi Teva, Fuan Pharmaceutical Group and Fujian Yewpark Biological etc. Sanofi is the global leader in this industry. According to our research, Sanofi had provided 845.8 Kg cabazitaxel API in 2017, which account for 95.32% of global market.
The worldwide market for Cabazitaxel is expected to grow at a CAGR of roughly 5.4% over the next five years, will reach 230 million US$ in 2024, from 170 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Cabazitaxel in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers
- Sanofi
- Tapi Teva
- Fuan Pharmaceutical Group
- Fujian Yewpark Biological

Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
- Type I
- Type II

Market Segment by Applications, can be divided into
- Age Below 65
- Age Above 65

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Cabazitaxel product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Cabazitaxel, with price, sales, revenue and global market share of Cabazitaxel in 2017 and 2018.
Chapter 3, the Cabazitaxel competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Cabazitaxel breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Cabazitaxel market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Cabazitaxel sales channel, distributors, customers, research findings and conclusion, appendix and data source.